Literature DB >> 9326613

A transformation-associated complex involving tyrosine kinase signal adapter proteins and caldesmon links v-erbB signaling to actin stress fiber disassembly.

M J McManus1, W L Lingle, J L Salisbury, N J Maihle.   

Abstract

The avian erythroblastosis viral oncogene (v-erbB) encodes a receptor tyrosine kinase that possesses sarcomagenic and leukemogenic potential. We have expressed transforming and nontransforming mutants of v-erbB in fibroblasts to detect transformation-associated signal transduction events. Coimmunoprecipitation and affinity chromatography have been used to identify a transformation-associated, tyrosine phosphorylated, multiprotein complex. This complex consists of Src homologous collagen protein (Shc), growth factor receptor binding protein 2 (Grb2), son of sevenless (Sos), and a novel tyrosine phosphorylated form of the cytoskeletal regulatory protein caldesmon. Immunofluorescence localization studies further reveal that, in contrast to the distribution of caldesmon along actin stress fibers in normal fibroblasts, caldesmon colocalizes with Shc in plasma membrane blebs in transformed fibroblasts. This colocalization of caldesmon and Shc correlates with actin stress fiber disassembly and v-erbB-mediated transformation. The tyrosine phosphorylation of caldesmon, and its association with the Shc-Grb2-Sos signaling complex directly links tyrosine kinase oncogenic signaling events with cytoskeletal regulatory processes, and may define one mechanism regulating actin stress fiber disassembly in transformed cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326613      PMCID: PMC23463          DOI: 10.1073/pnas.94.21.11351

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Characterization of mitotically phosphorylated caldesmon.

Authors:  Y Yamakita; S Yamashiro; F Matsumura
Journal:  J Biol Chem       Date:  1992-06-15       Impact factor: 5.157

2.  In-gel digestion of proteins for internal sequence analysis after one- or two-dimensional gel electrophoresis.

Authors:  J Rosenfeld; J Capdevielle; J C Guillemot; P Ferrara
Journal:  Anal Biochem       Date:  1992-05-15       Impact factor: 3.365

3.  Analysis of cell division using fluorescently labeled actin and myosin in living PtK2 cells.

Authors:  J M Sanger; B Mittal; J S Dome; J W Sanger
Journal:  Cell Motil Cytoskeleton       Date:  1989

Review 4.  Caldesmon: possible functions in microfilament reorganization during mitosis and cell transformation.

Authors:  S Yamashiro; K Yoshida; Y Yamakita; F Matsumura
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

5.  Modulation of erbB kinase activity and oncogenic potential by single point mutations in the glycine loop of the catalytic domain.

Authors:  H K Shu; C M Chang; L Ravi; L Ling; C M Castellano; E Walter; R J Pelley; H J Kung
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

6.  Early changes in the distribution and organization of microfilament proteins during cell transformation.

Authors:  C B Boschek; B M Jockusch; R R Friis; R Back; E Grundmann; H Bauer
Journal:  Cell       Date:  1981-04       Impact factor: 41.582

7.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

8.  Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor.

Authors:  L Buday; J Downward
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

9.  Phosphorylation of caldesmon77 by protein kinase C in vitro and in intact human platelets.

Authors:  D W Litchfield; E H Ball
Journal:  J Biol Chem       Date:  1987-06-15       Impact factor: 5.157

10.  Molecular characterization of three erbB transducing viruses generated during avian leukosis virus-induced erythroleukemia: extensive internal deletion near the kinase domain activates the fibrosarcoma- and hemangioma-inducing potentials of erbB.

Authors:  M A Raines; N J Maihle; C Moscovici; M G Moscovici; H J Kung
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

View more
  6 in total

1.  EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism.

Authors:  G Pines; P H Huang; Y Zwang; F M White; Y Yarden
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

Review 2.  Diversification of caldesmon-linked actin cytoskeleton in cell motility.

Authors:  Taira Mayanagi; Kenji Sobue
Journal:  Cell Adh Migr       Date:  2011-03-01       Impact factor: 3.405

3.  Caldesmon inhibits nonmuscle cell contractility and interferes with the formation of focal adhesions.

Authors:  D M Helfman; E T Levy; C Berthier; M Shtutman; D Riveline; I Grosheva; A Lachish-Zalait; M Elbaum; A D Bershadsky
Journal:  Mol Biol Cell       Date:  1999-10       Impact factor: 4.138

4.  Hela l-CaD is implicated in the migration of endothelial cells/endothelial progenitor cells in human neoplasms.

Authors:  Ping-Pin Zheng; Marcel van der Weiden; Johan M Kros
Journal:  Cell Adh Migr       Date:  2007-04-24       Impact factor: 3.405

5.  Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array.

Authors:  Paul J Gardina; Tyson A Clark; Brian Shimada; Michelle K Staples; Qing Yang; James Veitch; Anthony Schweitzer; Tarif Awad; Charles Sugnet; Suzanne Dee; Christopher Davies; Alan Williams; Yaron Turpaz
Journal:  BMC Genomics       Date:  2006-12-27       Impact factor: 3.969

6.  Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein.

Authors:  Dehuang Guo; Qinqin Xu; Sarabjot Pabla; John Koomen; Paul Biddinger; Ashok Sharma; Simarjot Pabla; Rafal Pacholczyk; Chien-Chung Chang; Kevin Friedrich; Kamran Mohammed; Robert C Smallridge; John A Copland; Jin-Xiong She; Paul M Weinberger
Journal:  Int J Mol Sci       Date:  2018-02-14       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.